Feb 17, 2023 / 09:30PM GMT
Operator
Good day, and welcome to the Travere Therapeutics Corporate Update Call. Today's call is being recorded. At this time, I'd like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi.
Naomi Eichenbaum -
Thank you, and thank you all for joining us today. Earlier today, we announced the accelerated approval of FILSPARI. A copy of the press release, along with the slides that we'll be referencing on today's call (inaudible). Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric for the prepared remarks will be our Chief Medical Officer, Dr. Jula Inrig; our Chief Commercial Officer, Peter Heerma; Our SVP of Research and Development, Bill Rote; and our Chief Financial Officer, Chris Cline.
Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not
Travere Therapeutics Inc FDA Accelerated Approval of FILSPARI (Sparsentan) Call Transcript
Feb 18, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers